Journal article
Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles
Abstract
The discoveries that cyclooxygenase (COX)-2 is an inducible form of COX involved in inflammation and that COX-1 is the major isoform responsible for the production of prostaglandins (PGs) in the gastrointestinal tract have provided a rationale for the development of specific COX-2 inhibitors as a new class of anti-inflammatory agents with improved gastrointestinal tolerability. In the present study, the preclinical pharmacological and …
Authors
Chan C-C; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY
Journal
Journal of Pharmacology and Experimental Therapeutics, Vol. 290, No. 2, pp. 551–560
Publisher
Elsevier
Publication Date
8 1999
DOI
10.1016/s0022-3565(24)34934-1
ISSN
0022-3565
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
12-Hydroxy-5,8,10,14-eicosatetraenoic AcidAnimalsArachidonate 15-LipoxygenaseArachidonic AcidArthritis, ExperimentalBlood PlateletsCOS CellsCell LineCricetinaeCyclooxygenase 2Cyclooxygenase 2 InhibitorsCyclooxygenase InhibitorsDigestive SystemDogsEdemaFemaleHumansHyperalgesiaIn Vitro TechniquesIsoenzymesLactonesLeukotriene B4MaleMembrane ProteinsMicrosomesProstaglandin-Endoperoxide SynthasesRatsRats, Inbred LewSaimiriSulfones